Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(415 sites)

United States

Local Institution - 1029, Homewood, Alabama

Local Institution - 1-13H98LK9, Chandler, Arizona

Local Institution - 1227, Chandler, Arizona

Local Institution - 1116, Chandler, Arizona

Local Institution - 1247, Gilbert, Arizona